Cultivation of new genetically engineered maize could cause problems in the EU
Monday, 26 March 2012
Munich/Brussels
Today Testbiotech is publishing a new backgrounder warning that the insecticide producing genetically engineered maize MON88017 might help pest insects become even more harmful. Researchers in a US laboratory have shown that the pest insects, known as corn rootworm, may not only become resistant to the insecticide producing maize plants, but the development of the larvae can be speeded up and fertility higher. Thus, commercial cultivation of these plants could result in helping the pest insects that are also known as the 'one billion dollar bug', to spread even quicker in the fields.
Testbiotech, supported by Corporate Observatory Europe (CEO), is today filing a new complaint with the EU Ombudsman questioning the independence of the chair of the panel of experts tasked with assessing the risk of new genetically engineered plants entering the European Union. Harry Kuiper has chaired the GMO Panel at the European Food Safety Authority (EFSA) since 2003 but has also maintained strong ties with International Life Sciences Institute (ILSI) including taking part in a task force led by a Monsanto employee.
The European Commission has recommended that one of Europe's chief food lobbyists – who is also a former Monsanto employee – sits on the management board of the European Food Safety Authority (EFSA). Testbiotech and Corporate Europe Observatory say that the appointment of Mella Frewen, lobby chief at FoodDrinkEurope (previously known as the CIAA) will create a conflict of interests for the food agency's management board.
5.3. 2012 The European Commission is planning to adopt new regulation on the risk assessment of genetically engineered plants used in food and feed. However, the standards are not sufficiently rigorous to exclude risks to human health and the environment. Testbiotech published a tabled overview on some deficiencies on 25 of January 2012 (http://www.testbiotech.org/en/node/613). After a meeting with the Commission on 14 of February, Testbiotech continues to maintain the concerns.